Jinan Zhuocheng Bio-Tech Co., Ltd.

Industry News | 2026 — China’s innovative pharmaceutical sector is accelerating its global expansion, with overseas transactions reaching unprecedented levels in the first half of 2026. According to industry data, the total value of China-originated innovative drug out-licensing and partnership deals reached approximately US$99.7 billion, with disclosed upfront payments exceeding US$6.45 billion. In the first quarter alone, transaction value reached US$61.4 billion, surpassing the total value recorded for the entire year of 2024.

Beyond the impressive figures, the more significant change lies in the transformation of the global cooperation model. Traditionally, Chinese pharmaceutical companies mainly relied on the License-out model, transferring overseas rights of innovative drug candidates to multinational pharmaceutical companies in exchange for upfront payments and milestone payments. While this approach helped accelerate the international commercialization of Chinese-developed medicines, it also meant that domestic companies often gave up part of their long-term commercial value.

In 2026, however, the industry landscape is shifting toward deeper strategic partnerships. The Co-Co model (Co-development and Co-commercialization) is gaining momentum, with multinational pharmaceutical companies increasingly choosing to jointly develop and commercialize innovative assets with Chinese partners rather than simply acquiring overseas rights.

For example, the collaboration between Innovent Biologics and Pfizer includes multiple key programs based on global joint development, allowing both parties to share commercialization benefits in major international markets. Similarly, Hengrui Pharmaceuticals and Bristol Myers Squibb (BMS) have established cooperation involving multiple jointly developed innovative drug programs. These partnerships demonstrate that multinational companies are no longer simply purchasing individual drug assets from China but are increasingly integrating with Chinese companies’ technology platforms and early-stage innovation pipelines.

Industry analysts believe this shift reflects a fundamental change in the position of Chinese pharmaceutical companies within the global innovation ecosystem. In the past, Chinese companies were often viewed primarily as cost-efficient development partners. Today, companies with strong innovation capabilities, differentiated pipelines, and advanced technology platforms are increasingly being recognized as strategic partners by global pharmaceutical leaders.

The transformation is also expected to benefit companies across the pharmaceutical service ecosystem. Following several years of industry restructuring and capacity adjustments, the global CXO (Contract Research Organization and Contract Development and Manufacturing Organization) sector has gradually moved toward supply optimization. With renewed demand for global drug development, companies with international compliance capabilities, advanced technologies, and high-quality service platforms are expected to see improved profitability.

However, the rapid expansion of overseas opportunities is also intensifying competition. The next phase of global expansion will increasingly favor companies with genuine technological advantages, differentiated drug pipelines, and strong international development capabilities. Companies relying primarily on imitation or follow-on strategies may find it increasingly difficult to compete in the global market.

Overall, China’s pharmaceutical globalization is entering a new stage. The industry is moving beyond simply exporting products and toward exporting innovation capabilities, technology platforms, and integrated global development models. Companies that can continuously deliver innovative assets, international partnerships, and global commercialization capabilities are expected to become the leading forces driving China’s pharmaceutical industry onto the world stage.